

Supporting Information

Iodoferrocene as partner in *N*-arylation of amides

Lingaswamy Kadari,^{a,b} William Erb,^{*a} Thierry Roisnel,^a

Palakodety Radha Krishna ^{*b} and Florence Mongin ^a

^a *Univ Rennes, CNRS, ISCR (Institut des Sciences Chimiques de Rennes) - UMR 6226, F-35000 Rennes, France*

^b *Organic Synthesis and Process Chemistry Division, CSIR-Indian Institute of Chemical Technology, Hyderabad, 500007, India*

E-mails: william.erb@univ-rennes1.fr, prkgenius@iict.res.in

Table of Contents

Putative palladium complex synthesis	p. S2
NMR spectra of compounds 2-Me , 2-cPr , 2-<i>t</i>Bu , 2-CH₂NEt₂ , 2-CF₃ , 2-Ph , 2-4OMe , 2-4NO₂ , 2-3OMe , 2-3Cl , 2-4F , 2-2Me , 2-Naph , 2-Fc , 2-2Th , 2-4Py , 2-Acry , 2-Pyrr , 2-Azet , 2-Pipe , 2-Azep , 2-AcFc , 2-3OMeMe , 2-3ClMe , 2-PhMe , 2-3ClBn , 2-PF1 and 2-PF2	p. S6
ORTEP diagrams (50% probability) of compounds 2-Me , 2-cPr , 2-CH₂NEt₂ , 2-CF₃ , 2-Ph , 2-4OMe , 2-4NO₂ , 2-3Cl , 2-4F , 2-Pyrr , 2-Azet , 2-Pipe , 2-Azep , 2-AcFc , 2-3OMeMe , 2-3ClMe , 2-PhMe and 2-3ClBn	p. S110
References and Notes	p. S119

Putative palladium complex synthesis

A Schlenk tube containing iodoferrocene (62.4 mg, 0.20 mmol, 1.00 equiv), palladium acetate (44.9 mg, 0.20 mmol, 1.00 equiv), cataCXium® (71.7 mg, 0.20 mmol, 1.00 equiv) and thallium carbonate (187.5 mg, 0.20 mmol, 1.00 equiv) was subjected to three cycles of vacuum/argon before degassed toluene (1.0 mL) was added. The Schlenk tube was isolated from the manifold and was heated at 110 °C overnight. The reaction mixture was cooled to rt and was directly purified by column chromatography on silica, eluting with petroleum ether-AcOEt (10:1 to 80:20) to give the complex as a dark red solid (35 mg).


^1H NMR (500 MHz, CDCl_3) δ (ppm) 0.88 (t, $J = 7.2$ Hz, 3H, CH_3), 1.29 (m, 2H), 1.77-1.69 (m, 14H), 2.03 (br s, 8H), 2.23 (br s, 12H), 4.28 (s, 2H, 2 x FcCH), 4.56 (s, 2H, 2 x FcCH), 4.61 (s, 5H, Cp).

^{13}C NMR (125 MHz, CDCl_3) δ (ppm) 14.0 (s), 22.7 (d, $J = 21.1$ Hz), 25.3 (d, $J = 13.5$ Hz), 28.9 (d, $J = 9.0$ Hz), 28.9 (d, $J = 9.0$ Hz), 29.7 (s), 29.8 (s), 36.3 (s), 40.3 (s), 42.3 (d, $J = 15.8$ Hz), 67.1 (s, 2 x FcCH), 70.0 (s, Cp), 75.3 (d, $J = 4.2$ Hz, 2 x FcCH).


See NMR spectra p. 3-5.

Despite all our efforts, we were not able to grow crystals suitable for crystallography due to the high solubility of the compound in common organic solvents, as already noticed by Manners on related complexes.¹ Although full elucidation of the complex structure by NMR analysis was not possible, the spectra obtained support the formation of an oxidative addition complex: ferrocenic protons appeared deshielded by ^1H NMR spectroscopy, as already observed on related complex,² while a coupling was noticed between phosphorous and the ferrocenic carbons by ^{13}C NMR spectroscopy. NOESY NMR experiment further supports such complex formation as a correlation between ferrocenic proton, adjacent to the palladium center, and two aliphatic signals, tentatively assigned to be part of the adamantyl moiety and butyl chain (2.23 and 1.77-1.69 ppm, respectively) was observed.³


Considering the cataCXium® complexes reported in the literature,³ a dimeric structure of such as complex A might be relevant. However, as thallium carbonate used as base is proposed to precipitate iodides,^{4, 5} a structure such as complex B might also be possible.




^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (500 MHz, CDCl_3)




^{31}P NMR (202 MHz, CDCl_3) – H_3PO_4 (85%) as internal reference



^{31}P NMR (202 MHz, CDCl_3)




NOESY NMR (500 MHz, CDCl₃)




NMR Spectra


N-Ferrocenylacetamide (2-Me, mixture of rotamers)




^1H NMR (300 MHz, $(\text{CD}_3)_2\text{CO}$)




^1H NMR (300 MHz, CDCl_3)




^{13}C NMR (75 MHz, CDCl_3)




N-(Ferrocenyl)cyclopropanecarboxamide (2-cPr)




^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




COSY (500 MHz, CDCl₃)




HSQC (500 MHz, CDCl₃)




HMBC (500 MHz, CDCl₃)




NOESY (500 MHz, (CD₃)₂SO)




N-Ferrocenylpivalamide (2-*t*Bu)




^1H NMR (500 MHz, $(\text{CD}_3)_2\text{CO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{CO}$)




DEPT 135 (126 MHz, (CD₃)₂CO)




COSY (500 MHz, (CD₃)₂CO)




HSQC (500 MHz, (CD₃)₂CO)




HMBC (500 MHz, (CD₃)₂CO)




***N*-Ferrocenylformamide (2-H; 2.8:1 (*cis/trans*) mixture of rotamers)**




^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)



HSQC (500 MHz, (CD₃)₂SO)





HMBC (500 MHz, (CD₃)₂SO)




N,N-Diferrocenylformamide


¹H NMR (500 MHz, (CD₃)₂SO)




¹³C NMR (126 MHz, (CD₃)₂SO)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)




HMBC (500 MHz, (CD₃)₂SO)




2-(Diethylamino)-*N*-ferrocenylacetamide (2-CH₂NEt₂)




¹H NMR (500 MHz, (CD₃)₂SO)




¹³C NMR (126 MHz, (CD₃)₂SO)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)




HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




N-(Ferrocenyl)trifluoroacetamide (2-CF₃)




¹H NMR (500 MHz, (CD₃)₂CO)




¹³C NMR (126 MHz, (CD₃)₂CO)




DEPT 135 (126 MHz, (CD₃)₂CO)




¹⁹F NMR (470 MHz, (CD₃)₂CO)




^{19}F NMR (282 MHz, CDCl_3)




COSY (500 MHz, $(\text{CD}_3)_2\text{CO}$)



HSQC (500 MHz, (CD₃)₂CO)




HMBC (500 MHz, (CD₃)₂CO)




N-Ferrocenylbenzamide (2-Ph)


^1H NMR (300 MHz, CDCl_3)




^{13}C NMR (75 MHz, CDCl_3)




DEPT 135 (75 MHz, CDCl₃)




COSY (300 MHz, CDCl₃)



HSQC (300 MHz, CDCl₃)




HMBC (300 MHz, CDCl₃)




N-Ferrocenyl-4-methoxybenzamide (2-4OMe)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)



HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




N-Ferrocenyl-4-nitrobenzamide (2-4NO₂)


¹H NMR (500 MHz, (CD₃)₂SO)




¹³C NMR (126 MHz, (CD₃)₂SO)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)



HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




N-Ferrocenyl-3-methoxybenzamide (2-3OMe)


^1H NMR (300 MHz, CDCl_3)




^{13}C NMR (75 MHz, CDCl_3)




DEPT 135 (75 MHz, CDCl₃)




COSY (300 MHz, CDCl₃)



HSQC (300 MHz, CDCl₃)




HMBC (300 MHz, CDCl₃)




3-Chloro-*N*-ferrocenylbenzamide (2-3Cl)


^1H NMR (300 MHz, CDCl_3)




^{13}C NMR (75 MHz, CDCl_3)




DEPT 135 (75 MHz, CDCl₃)




COSY (300 MHz, CDCl₃)



HSQC (300 MHz, CDCl₃)




HMBC (300 MHz, CDCl₃)




N-Ferrocenyl-4-fluorobenzamide (2-4F)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)



HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




N-Ferrocenyl-2-methylbenzamide (2-2Me)


^1H NMR (300 MHz, CDCl_3)




^{13}C NMR (75 MHz, CDCl_3)




DEPT 135 (75 MHz, CDCl₃)




COSY (300 MHz, CDCl₃)




HSQC (300 MHz, CDCl₃)



HMBC (300 MHz, CDCl₃)




ROESY (300 MHz, CDCl₃)




N-Ferrocenyl-2-naphthalenecarboxamide (2-Naph)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)



HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




N-(Ferrocenyl)ferrocenecarboxamide (2-Fc)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)



HSQC (500 MHz, (CD₃)₂SO)




HMBC (500 MHz, (CD₃)₂SO)




N-Ferrocenyl-2-thiophenecarboxamide (2-2Th)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)



HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




N-Ferrocenylisonicotinamide (2-4Py)


^1H NMR (400 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (100 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)



HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




3-(5-(1,3-Benzodioxolyl))-N-ferrocenylacrylamide (2-Acry)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)




HSQC (500 MHz, (CD₃)₂SO)



HMBC (500 MHz, (CD₃)₂SO)




NOESY (500 MHz, (CD₃)₂SO)




Accepted manuscript

N-Ferrocenylpyrrolidinone (2-Pyrr)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{CO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{CO}$)




DEPT 135 (126 MHz, (CD₃)₂CO)




COSY (500 MHz, (CD₃)₂CO)




HSQC (500 MHz, (CD₃)₂CO)




HMBC (500 MHz, (CD₃)₂CO)




NOESY (500 MHz, (CD₃)₂CO)




N-Ferrocenyl-2-azetidinone (2-Azet)




^1H NMR (300 MHz, CDCl_3)




^{13}C NMR (75 MHz, CDCl_3)




DEPT 135 (75 MHz, CDCl₃)




COSY (300 MHz, CDCl₃)



HSQC (300 MHz, CDCl₃)




HMBC (300 MHz, CDCl₃)




N-Ferrocenyl-2-piperidinone (2-Pipe)


^1H NMR (400 MHz, $(\text{CD}_3)_2\text{CO}$)




^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{CO}$)




COSY (400 MHz, (CD₃)₂CO)



HSQC (400 MHz, (CD₃)₂CO)




HMBC (400 MHz, (CD₃)₂CO)




N-(Ferrocenyl)hexahydro-2-azepinone (2-Azep)


^1H NMR (400 MHz, $(\text{CD}_3)_2\text{CO}$)




^{13}C NMR (100 MHz, $(\text{CD}_3)_2\text{CO}$)




DEPT 135 (100 MHz, (CD₃)₂CO)




COSY (400 MHz, (CD₃)₂CO)



HSQC (400 MHz, (CD₃)₂CO)




HMBC (400 MHz, (CD₃)₂CO)




N,N-Diferrocenylacetamide (2-AcFc)


^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




DEPT 135 (126 MHz, CDCl₃)




COSY (500 MHz, CDCl₃)




HSQC (500 MHz, CDCl₃)



HMBC (500 MHz, CDCl₃)




NOESY (500 MHz, CDCl₃)




Accepted manuscript

N-Ferrocenyl-3-methoxy-*N*-methylbenzamide (2-3OMeMe)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)



HSQC (500 MHz, (CD₃)₂SO)




HMBC (500 MHz, (CD₃)₂SO)




3-Chloro-*N*-ferrocenyl-*N*-methylbenzamide (2-3ClMe)


^1H NMR (500 MHz, $(\text{CD}_3)_2\text{SO}$)




^{13}C NMR (126 MHz, $(\text{CD}_3)_2\text{SO}$)




DEPT 135 (126 MHz, (CD₃)₂SO)




COSY (500 MHz, (CD₃)₂SO)



HSQC (500 MHz, (CD₃)₂SO)




HMBC (500 MHz, (CD₃)₂SO)




N-Ferrocenyl-*N*-methylbenzamide (2-PhMe)


^1H NMR (300 MHz, CDCl_3)




^{13}C NMR (75 MHz, CDCl_3)




DEPT 135 (75 MHz, CDCl₃)




COSY (300 MHz, CDCl₃)



HSQC (300 MHz, CDCl₃)




HMBC (300 MHz, CDCl₃)




N-Benzyl-3-chloro-*N*-ferrocenylbenzamide (2-3ClBn)


^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




DEPT 135 (126 MHz, CDCl₃)



COSY (500 MHz, CDCl₃)




HSQC (500 MHz, CDCl₃)



HMBC (500 MHz, CDCl₃)




NOESY (500 MHz, CDCl₃)




Accepted manuscript

N-Benzyl-3-(2,5-dimethoxyphenyl)-*N*-ferrocenylbenzamide (2-PF1)


^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




DEPT 135 (126 MHz, CDCl₃)




COSY (500 MHz, CDCl₃)




HSQC (500 MHz, CDCl₃)



HMBC (500 MHz, CDCl₃)




NOESY (500 MHz, CDCl₃)




N-Benzyl-*N*-ferrocenyl-3-(*N*-morpholino)benzamide (2-PF2)


^1H NMR (500 MHz, CDCl_3)




^{13}C NMR (126 MHz, CDCl_3)




DEPT 135 (126 MHz, CDCl₃)




COSY (500 MHz, CDCl₃)




HSQC (500 MHz, CDCl₃)



HMBC (500 MHz, CDCl₃)




NOESY (500 MHz, CDCl₃)




ORTEP Diagrams (50% probability)


N-Ferrocenylacetamide (2-Me; mixture of rotamers)




N-(Ferrocenyl)cyclopropanecarboxamide (2-cPr)




2-(Diethylamino)-*N*-ferrocenylacetamide (2-CH₂NEt₂)




***N*-(Ferrocenyl)trifluoroacetamide (2-CF₃)**




***N*-Ferrocenylbenzamide (2-Ph)**




***N*-Ferrocenyl-4-methoxybenzamide (2-4OMe)**




***N*-Ferrocenyl-4-nitrobenzamide (2-4NO₂)**




3-Chloro-*N*-ferrocenylbenzamide (2-3Cl)




***N*-Ferrocenyl-4-fluorobenzamide (2-4F)**




***N*-Ferrocenylpyrrolidinone (2-Pyrr)**




N-Ferrocenyl-2-azetidinone (2-Azet)




N-Ferrocenyl-2-piperidinone (2-Pipe)




***N*-(Ferrocenyl)hexahydro-2-azepinone (2-Azep)**




***N,N*-Diferrocenylacetamide (2-AcFc)**




***N*-Ferrocenyl-3-methoxy-*N*-methylbenzamide (2-3OMeMe)**




3-Chloro-*N*-ferrocenyl-*N*-methylbenzamide (2-3ClMe)



N-Ferrocenyl-*N*-methylbenzamide (2-PhMe)



N-Benzyl-3-chloro-*N*-ferrocenylbenzamide (2-3ClBn)



References

1. I. Matas, G. R. Whittell, B. M. Partridge, J. P. Holland, M. F. Haddow, J. C. Green and I. Manners, *J. Am. Chem. Soc.*, 2010, **132**, 13279-13289.
2. C. Amatore, B. Godin, A. Jutand, B. Ferber, S. Top and G. Jaouen, *Organometallics*, 2007, **26**, 3887-3890.
3. A. G. Sergeev, A. Zapf, A. Spannenberg and M. Beller, *Organometallics*, 2008, **27**, 297-300.
4. J. Uenishi, J. M. Beau, R. W. Armstrong and Y. Kishi, *J. Am. Chem. Soc.*, 1987, **109**, 4756-4758.
5. H. Chaumeil, S. Signorella and C. Le Drian, *Tetrahedron*, 2000, **56**, 9655-9662.

Accepted manuscript